BioMmune Appoints Dr. Patrick Gray as New Chief Executive Officer and President
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/22/16 -- BioMmune Technologies Inc. ("BioMmune" or the "Company") (TSX VENTURE: IMU), a company focused on harnessing the body''s immune system to fight cancer and autoimmune diseases, announces that Dr. Patrick W. Gray has been appointed to serve as Chief Executive Officer and President. Dr. Gray has worked in the biotechnology industry for the past 35 years with extensive experience in drug discovery at Genentech, ICOS, and Macrogenics. He also has previous executive experience as Chief Scientific Officer, CEO, and as member of Boards of Director. His previous drug discovery efforts led to the development of the Hepatitis B vaccine and multiple drugs (such as Interferon-gamma) and drug targets (CCR5 and PI3 Kinase p110delta). Former BioMmune CEO and President, Dr. Reinhard Gabathuler has resigned his positions to become Senior Vice-President of Business Development. In his new role, Dr. Gray will lead the company''s R&D programs and financing activities, whereas Dr. Gabathuler will lead the company''s partnering and business development activities. BioMmune anticipates increasing partnering efforts resulting from its progress in its oncology and immunology programs.
ABOUT BIOMMUNE TECHNOLOGIES INC.
BioMmune focuses on cancer, infectious and autoimmune diseases. Three significant technologies are:
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may we may not be successful in either preclinical or clinical trials and not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at . Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
On Behalf of the Board of Directors,
Dr. Karoly Nikolich, Director
(i)Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
BioMmune Technologies Inc.
Dr. Patrick Gray
206-650-6575
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.04.2016 - 06:45 Uhr
Sprache: Deutsch
News-ID 1429915
Anzahl Zeichen: 3438
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 204 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioMmune Appoints Dr. Patrick Gray as New Chief Executive Officer and President
"
steht unter der journalistisch-redaktionellen Verantwortung von
BioMmune Technologies Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
